Table 1. Clinico-pathological details of affected family members.
| ID | Stage | Treatment | Age at diagnosis | HLA type | Subtype, EBV status |
|---|---|---|---|---|---|
| IV-f | 2A | 6 × ABVD | 22 | A*02:01,A*02:01, B*07:02,B*13:02, C*06:02,C*07:02, DRB1*07:01,DRB1*15:01, DRB4*01, DRB5*01, DQB1*02:02,DQB1*06:02, DPB1*04:01:01,DPB1*04:02 | NSHL, LMP1 negative. |
| IV-b | 2A | 6 × ABVD, radiotherapy | 18 | A*01:01,A*02:01, B*08:01,B*44:02, C*05:01,C*07:01, DRB1*01:01,DRB1*03:01, DRB3*01, DQB1*05:01,DQB1*02:01, DPB1*04:01:01 | NSHL, unknown |
| III-g | 2A | 3 × ABVD, radiotherapy | 31 | A*03:01, B*07:02,B*49:01, C*07:01,C*07:02, DRB1*04:01,DRB1*15:01, DRB4*01, DRB5*01, DQB1*06:02,DQB1*03:01, DPB1*04:01 | NSHL, unknown |
| IV-g | 4B | 2 × ABVD, 6 × BEACOPPe, IFRT | 25 | A*03:01,A*25:01, B*07:02,B*18:01, C*07:02,C*12:03, DRB1*15:01, DRB5*01:01, DQB1*06:02, DPB1*04:01,DPB1*145:01 | NSHL, EBER negative. |
| III-a | NA | NA | 33 | NA | NA |
ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, cyclophosphamide, adriamycin, vincristine, procarbazine, prednisolone; IFRT, involved-field radiotherapy, LMP1, latent membrane protein 1; EBV, Epstein–Barr virus; EBER, - Epstein–Barr virus-encoded small RNAs; NSHL, nodular sclerosis Hodgkin lymphoma; NA, not available.